Technical Analysis for VEGPF - Vectura Group Plc

Grade Last Price % Change Price Change
grade B 1.0581 -2.93% -0.0319
VEGPF closed down 2.93 percent on Monday, December 2, 2019, on 1.5 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Up Up
Historical VEGPF trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Stochastic Reached Overbought Strength 0.00%
Overbought Stochastic Strength 0.00%
Gapped Down Weakness 0.00%
MACD Bullish Centerline Cross Bullish -2.93%
Bollinger Band Squeeze Range Contraction -2.93%
Narrow Range Bar Range Contraction -2.93%
BB Squeeze + Upper Band Touch Range Contraction -2.93%
Above Upper BB Strength -2.93%
Older signals for VEGPF ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta and Anoro Ellipta for the treatment of COPD. Its generic partnering products include flutiform, VR315, VR506, VR730, VR632, VR2081, VR410, and Ellipta for the treatment of asthma; and Phase I clinical stage product is the VR475 (US) for the treatment of severe adult asthma. The company's Phase II clinical stage products comprise VR465 for treating respiratory syncytial virus infection; VR647 for the treatment of paediatric asthma; and VR736 for the treatment severe influenza. Its Phase III clinical stage products include QVM149 for the treatment of asthma; and VR475 (EU) for the treatment of severe adult asthma. The company also provides dry powder inhalers; pressurized meter dose inhalers; and smart nebulizers. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.
Medicine Health Clinical Medicine Pharmaceutical Products European Union Asthma Dosage Forms Chronic Obstructive Pulmonary Disease Respiratory Therapy Pulmonary Arterial Hypertension Chronic Lower Respiratory Diseases Combination Drugs Treatment Of Asthma And Chronic Obstructive Pulmonary Disease Clinical Stage Product Copd Clinical Stage Products Dry Powder Inhaler Ellipta Fluticasone Furoate/Vilanterol

Is VEGPF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 2.51
52 Week Low 0.845
Average Volume 68,987
200-Day Moving Average 0.0000
50-Day Moving Average 1.0078
20-Day Moving Average 1.0032
10-Day Moving Average 1.0074
Average True Range 0.0430
ADX 8.96
+DI 52.0906
-DI 44.8609
Chandelier Exit (Long, 3 ATRs ) 0.9810
Chandelier Exit (Short, 3 ATRs ) 1.0400
Upper Bollinger Band 1.0925
Lower Bollinger Band 0.9139
Percent B (%b) 0.81
BandWidth 17.8030
MACD Line 0.0074
MACD Signal Line -0.0032
MACD Histogram 0.0106
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.0581
Resistance 3 (R3) 1.0581 1.0581 1.0581
Resistance 2 (R2) 1.0581 1.0581 1.0581 1.0581
Resistance 1 (R1) 1.0581 1.0581 1.0581 1.0581 1.0581
Pivot Point 1.0581 1.0581 1.0581 1.0581 1.0581
Support 1 (S1) 1.0581 1.0581 1.0581 1.0581 1.0581
Support 2 (S2) 1.0581 1.0581 1.0581 1.0581
Support 3 (S3) 1.0581 1.0581 1.0581
Support 4 (S4) 1.0581